cfDNA Methylation for Early Neurodegeneration Detection

Neurodegenerative diseases remain difficult to detect and monitor with high precision. However, emerging sequencing-based methylation tools are enabling new ways to track the progression of these complex conditions.

In this on-demand webinar, speakers from Wasatch BioLabs and the University of Kansas Alzheimer’s Disease Research Center will explore how the analysis of cell-free DNA (cfDNA), powered by Oxford Nanopore Technologies, is advancing the detection and monitoring of neurodegenerative conditions such as Alzheimer’s and Parkinson’s.

• Understand how cfDNA methylation profiling using Oxford Nanopore sequencing enables accurate, cell-type–specific identification of neurodegenerative processes from blood
• Explore case studies from Wasatch BioLabs demonstrating early detection and differentiation of Alzheimer’s, Parkinson’s, and related disorders
• Discover how Oxford Nanopore sequencing technology uniquely supports native methylation detection and multiomic approaches, enabling new methods for precision medicine

Watch the webinar on nanoporetech.com